GPs are already using AI tools during appointments, and a major AI company is now seeking to expand their role to include discussing patients’ medicines. Multiple outlets report that about 40% of Australian GPs use an AI scribe to help with documentation, and that none of these AI scribes are approved by Australia’s medicines regulator, the TGA.
The funding push is also framed as a step beyond note-taking. The industry’s biggest player has raised $476 million to develop capabilities that could enable AI systems to support conversations about medications, rather than only recording what is said in the consultation.
Across the coverage, the common focus is on rapid adoption of AI in clinical workflows and the regulatory gap for current tools. Outlets differ mainly in emphasis: some highlight the extent of current AI scribe use, while others concentrate on what the newly funded system could do next in medication-related discussions.
